OakChart

Alto Neuroscience Inc

ANROHealthcare·Biotechnology·USA·Small·NYSE·Nov 12 • 3:59 PM ET

30.62-0.53 (-1.70%)
2026-11-13 13:18 CET
Market cap
$1.23B
Revenue, TTM
0.00 USD m
Net income, TTM
-95.18 USD m
Free cash flow, TTM
-79.68 USD m
EPS diluted, TTM
-2.49
Price / earnings
-
Compare

Price

ANRO against its 20, 50 and 200-day averages
Terms2050200BeatMiss
Patternshover a marker to name it
RS 68Sales 0.00Price0.0020.0030.002.2M4.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ANROclose 30.6220-day 24.2450-day 26.50200-day 24.6630.6252w high 37.4852-week range, not 6 months

18.3% under the 52-week high of 37.48 on 25 Aug 2026. 52-week low 10.80 on 14 Nov 2025. Last 15 sessions, 56.2% high to low

Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average

Setup. RS line 68
CANSLIM 3 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High
VCP 4 of 6 — fails: 52-Week High/Low: 0-10% below High; RSI (14): Not Overbought (<60)
Minervini 3 of 4 — fails: 52-Week High/Low: 0-10% below High
Zanger 3 of 5 — fails: 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5
Leaders 4 of 5 — fails: 52-Week High/Low: 0-10% below High
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 4 of 4
Accumulation 3 of 4 — fails: Institutional Transactions: Over +10%
Relative Strength 3 of 3

Profile

ANRO
52-week range, 74% of the way up
10.8037.48

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

IndexRUT
Employees68
IPOFeb 02, 2024
Beta1.36
ATR, 14d1.99
Rel volume0.00
Short float15.64%
Insider own9.40%
Inst own80.53%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap$1.23B
Enterprise Value926.87M
Income-95.18M
Sales0.00M
Book / share7.42
Cash / share7.96
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees68
IPOFeb 02, 2024

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book4.13
Price / cash3.85
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio18.12
Current Ratio18.12
Debt / equity0.06
Long-term debt / equity0.04
Options and shortYes / Yes

Earnings

Earnings / share-2.49
Earnings next year-2.71
Earnings next quarter-0.61
Earnings this year-15.73%
Earnings next year-6.85%
Earnings growth, 5 years-9.60%
Past earnings growth-26.47% -57.17%
Past sales growth- -
Earnings vs last year-8.20%
Sales vs last year-
Earnings vs last quarter-3.19%
Sales vs last quarter-
EarningsNov 10 AMC
Surprise19.82% -

Ownership

Insiders own9.40%
Insider trades-3.45%
Institutions own80.53%
Institution trades5.98%
Return on assets-40.20%
Return on equity-46.65%
Return on capital-30.84%
Gross Margin-
Operating margin-
Profit Margin-
20-day average26.33%
50-day average15.54%
200-day average24.15%

Technical

Shares out39.98M
Shares floating36.34M
Short / float15.64%
Short ratio9.36
Short interest5.68M
52-week high37.48 -18.3%
52-week low10.80 +183.5%
Volatility11.98% 7.55%
Average range1.99
Strength index68.54
Market sensitivity1.36
Relative volume0.00
Avg Volume607.41K
Volume0

Performance

Perf Week40.01%
Perf Month41.04%
Perf Quarter-4.73%
Perf Half Y29.80%
Perf YTD72.02%
Perf Year115.63%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recommendation1.27
Target Price38.88
Prev Close30.62
Price30.62
Change %0.00%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
May 22, 2026InitiatedWolfe ResearchOutperform
May 05, 2026InitiatedBofA SecuritiesBuy$35+14.3%
Jan 05, 2026ResumedChardan Capital MarketsBuy$30-2.0%
Nov 17, 2025InitiatedBTIG ResearchBuy
Sep 29, 2025InitiatedChardan Capital MarketsBuy$15-51.0%
Oct 23, 2024DowngradeWedbushOutperform → Neutral$29 → $4-86.9%
Oct 23, 2024DowngradeRodman & RenshawBuy → Neutral
Sep 03, 2024InitiatedWedbushOutperform$29-5.3%
Feb 27, 2024InitiatedWilliam BlairOutperform
Feb 27, 2024InitiatedTD CowenOutperform

Peers

Mkt cap
TickerCompanyMkt cap
SPTXSeaport Therapeutics Inc1.08B
NMRANeumora Therapeutics Inc81.36M
MPLTMapLight Therapeutics Inc392.92M
DFTXDefinium Therapeutics Inc4.52B
HELPHelus Pharma Inc677.13M
RLMDRelmada Therapeutics Inc443.75M
AXSMAxsome Therapeutics Inc7.59B
DRUGBright Minds Biosciences Inc224.31M
VTGNVistagen Therapeutics Inc7.98M
MNOVMedicinova Inc68.91M

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Smith Nicholas ConradPRESIDENT AND CFOOct 02 '26Option Exercise2.3255,000127,60079,060Oct 05 04:59 PM
Smith Nicholas ConradPRESIDENT AND CFOSep 29 '26Option Exercise2.35110,830260,450134,890Oct 01 09:33 PM
Smith Nicholas ConradPRESIDENT AND CFOSep 30 '26Option Exercise2.3524,05656,53248,116Oct 01 09:33 PM
Smith Nicholas ConradPRESIDENT AND CFOSep 29 '26Sale26.58110,8302,946,15024,060Oct 01 09:33 PM
Smith Nicholas ConradPRESIDENT AND CFOSep 30 '26Sale25.8224,056621,09724,060Oct 01 09:33 PM
NICHOLAS SMITHOfficerSep 29 '26Proposed Sale26.66134,8863,596,061Sep 29 04:23 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
IWMiShares Russell 2000 Index FundAUM: 77.86B
VXFVanguard Extended Market Index ETFAUM: 30.79B
IWOiShares Russell 2000 Growth ETFAUM: 14.25B
IBBiShares Biotechnology ETFAUM: 11.39B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 530.07M
DWASInvesco Dorsey Wright SmallCap Momentum ETFAUM: 396.75M
SCHASchwab U.S. Small-Cap ETFAUM: 22.44B
VTWOVanguard Russell 2000 Index ETFAUM: 16.90B
PTHInvesco Dorsey Wright Healthcare Momentum ETFAUM: 292.59M

News

latest 14 of 200

Quarterly earnings

2026Q3 EPS -0.540 beat -0.674, from -0.520 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
EPS
0.0000-0.8002024Q4 EPS -0.520 against -0.64624Q42025Q1 EPS -0.560 against -0.60925Q12025Q2 EPS -0.650 against -0.59925Q22025Q3 EPS -0.520 against -0.66825Q32025Q4 EPS -0.460 against -0.53125Q42026Q1 EPS -0.800 against -0.53626Q12026Q2 EPS -0.650 against -0.73526Q22026Q3 EPS -0.540 against -0.67426Q3
Sales, USD millions
0.890-0.892024Q4 sales 0.00 against 0.0024Q42025Q1 sales 0.00 against 0.0025Q12025Q2 sales 0.00 against 0.0025Q22025Q3 sales 0.00 against 0.0025Q32025Q4 sales 0.00 against 0.0025Q42026Q1 sales 0.00 against 0.0026Q12026Q2 sales 0.00 against 0.0026Q22026Q3 sales 0.00 against 0.0026Q3

The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.

PeriodReportedEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mSurpriseYear-ago quarterAnalystsNext session
2026Q3ended 2026-09-302026-11-10 16:30-0.540-0.674-0.5400.000.00EPS -19.8% · sales -vs 2025Q3, year-ago quarter · EPS +3.8% · sales -11 EPS · 6 salesOpen +3.98% vs SPY +0.92%. Close +8.88% vs SPY +1.32%
2026Q2ended 2026-06-302026-08-12 16:30-0.650-0.735-0.6460.000.00EPS -11.5% · sales -vs 2025Q2, year-ago quarter · EPS 0.0% · sales -11 EPS · 7 salesOpen +2.81% vs SPY +0.31%. Close +10.69% vs SPY +0.70%
2026Q1ended 2026-03-312026-05-13 08:30-0.800-0.536-0.7980.000.00EPS +49.1% · sales -vs 2025Q1, year-ago quarter · EPS +42.9% · sales -11 EPS · 6 salesOpen -2.88% vs SPY +0.04%. Close -7.23% vs SPY +0.56%
2025Q4ended 2025-12-312026-03-16 08:30-0.460-0.531-0.5070.000.00EPS -13.4% · sales -vs 2024Q4, year-ago quarter · EPS -11.5% · sales -10 EPS · 6 salesOpen +1.17% vs SPY +0.92%. Close +9.12% vs SPY +1.02%
2025Q3ended 2025-09-302025-11-12 08:30-0.520-0.668-0.5230.000.00EPS -22.1% · sales -vs 2024Q3, year-ago quarter · EPS -16.1% · sales -8 EPS · 6 salesOpen 0.00% vs SPY +0.26%. Close +5.97% vs SPY +0.06%
2025Q2ended 2025-06-302025-08-13 16:30-0.650-0.599-0.6540.000.00EPS +8.6% · sales -vs 2024Q2, year-ago quarter · EPS +8.3% · sales -8 EPS · 5 salesOpen -1.92% vs SPY -0.33%. Close -0.32% vs SPY +0.01%
2025Q1ended 2025-03-312025-05-14 16:30-0.560-0.609-0.5610.000.00EPS -8.0% · sales -vs 2024Q1, year-ago quarter · EPS -26.3% · sales -7 EPS · 4 salesOpen 0.00% vs SPY -0.35%. Close +10.45% vs SPY +0.49%
2024Q4ended 2024-12-312025-03-20 16:30-0.520-0.646-0.5630.000.00EPS -19.5% · sales -vs 2023Q4, year-ago quarter · EPS -72.7% · sales -8 EPS · 6 salesOpen -2.23% vs SPY -1.10%. Close -1.49% vs SPY -0.27%
2024Q3ended 2024-09-302024-11-12 16:30-0.620-0.650-0.6220.000.00EPS -4.6% · sales --7 EPS · 4 salesOpen +2.67% vs SPY +0.08%. Close +0.67% vs SPY +0.05%
2024Q2ended 2024-06-302024-08-13 16:30-0.600-0.657-0.5950.000.00EPS -8.6% · sales --6 EPS · 3 salesOpen +0.22% vs SPY +0.15%. Close +6.01% vs SPY +0.32%
2024Q1ended 2024-03-312024-05-14 16:30-0.760-0.462-0.4990.000.00EPS +64.5% · sales --5 EPS · 2 salesOpen -1.13% vs SPY +0.48%. Close -2.26% vs SPY +1.24%
2023Q4ended 2023-12-312024-03-21 16:30-1.902-0.835-0.4170.000.00EPS +127.7% · sales --4 EPS · 2 salesOpen -2.05% vs SPY -0.02%. Close +5.41% vs SPY -0.19%
2026Q4ended 2026-12-31---0.613--0.00EPS - · sales -vs 2025Q4, year-ago quarter · EPS - · sales -11 EPS · 6 sales-
2027Q1ended 2027-03-31---0.659--0.00EPS - · sales -vs 2026Q1, year-ago quarter · EPS - · sales -8 EPS · 4 sales-
2027Q2ended 2027-06-30---0.678--0.00EPS - · sales -vs 2026Q2, year-ago quarter · EPS - · sales -8 EPS · 4 sales-
2027Q3ended 2027-09-30---0.668--0.00EPS - · sales -vs 2026Q3, year-ago quarter · EPS - · sales -8 EPS · 4 sales-

Annual earnings

2025FY EPS -2.190 beat -2.240, from -2.500 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
EPS
0.0000-9.7302023FY EPS -9.730 against -2.92520232024FY EPS -2.500 against -2.58620242025FY EPS -2.190 against -2.2402025
Sales, USD millions
0.890-0.892023FY sales 0.00 against 0.0020232024FY sales 0.00 against 0.0020242025FY sales 0.00 against 0.002025

Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.

earnings feed, not the snapshot. Not the statement ratio.

PeriodEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mP/E, earnings feed
2030FYestimate--0.956--225.73-
2029FYestimate--2.993--31.10-
2028FYestimate--2.883--0.00-
2027FYestimate--2.708--0.00-
2026FYestimate--2.535--0.00-
2025FY-2.190-2.240-2.1900.000.00-
2024FY-2.500-2.586-2.4970.000.00-
2023FY-9.730-2.925-1.3500.000.00-

Quarterly results

2026Q3 revenue 0.00, from 0.00 a year earlier
Revenue, USD millions
0.890-0.892024Q4 revenue 0.0024Q42025Q1 revenue 0.0025Q12025Q2 revenue 0.0025Q22025Q3 revenue 0.0025Q32025Q4 revenue 0.0025Q42026Q1 revenue 0.0026Q12026Q2 revenue 0.0026Q22026Q3 revenue 0.0026Q3

From the quarterly statement. Not an estimate.

Estimate revisions

Latest snapshot of each period and type. 2026FY E -2.53 per share.
PeriodTypeScaleDateMeanvs prior date
2026FYEper share2026-11-11-2.53-9.0%
2026Q4Eper share2026-11-11-0.61-11.9%
2026FYRper share2026-11-11-2.52-5.8%
2026Q4Rper share2026-11-11-0.61-7.4%
2026Q4Sper share2026-11-110.00-
2026Q3Eper share2026-10-28-0.670.0%
2026Q3Rper share2026-10-28-0.630.0%
2026FYSper share2026-08-290.00-
2026Q3Sper share2026-08-290.00-
2026Q2Eper share2026-08-05-0.730.0%
2026Q2Rper share2026-08-05-0.690.0%
2026Q2Sper share2026-07-270.00-
2026Q1Eper share2026-05-04-0.54-0.1%
2026Q1Rper share2026-05-04-0.56-0.8%
2026Q1Sper share2026-03-180.00-
2025FYEper share2026-03-03-2.240.0%
2025Q4Eper share2026-03-03-0.530.0%
2025Q4Rper share2026-01-27-0.560.0%
2025FYRper share2026-01-26-2.270.0%
2025FYSper share2025-11-120.00-
2025Q4Sper share2025-11-120.00-
2025Q3Eper share2025-10-28-0.670.0%
2025Q3Rper share2025-10-28-0.630.0%
2025Q3Sper share2025-09-260.00-
2025Q2Eper share2025-08-02-0.600.0%
2025Q2Rper share2025-08-02-0.590.0%
2025Q2Sper share2025-05-160.00-
2025Q1Sper share2025-04-250.00-
2025Q1Rper share2025-04-07-0.58-10.1%
2025Q1Eper share2025-04-04-0.61-4.2%
2024FYSper share2025-03-200.00-
2024Q4Sper share2025-03-200.00-
2024FYEper share2025-02-11-2.590.0%
2024Q4Eper share2025-02-11-0.65-0.1%
2024FYRper share2025-01-27-2.510.0%
2024Q4Rper share2025-01-27-0.640.0%
2024Q3Eper share2024-10-28-0.650.0%
2024Q3Rper share2024-10-28-0.680.0%
2024Q3Sper share2024-08-290.00-
2024Q2Eper share2024-07-29-0.660.0%
2024Q2Rper share2024-07-29-0.670.0%
2024Q2Sper share2024-05-150.00-
2024Q1Eper share2024-04-22-0.46-0.1%
2024Q1Rper share2024-03-22-0.47-3.8%
2024Q1Sper share2024-03-220.00-
2023FYEper share2024-02-26-2.93-75.2%
2023FYRper share2024-02-26-2.97-
2023FYSper share2024-02-260.00-

Estimate history

Annual
Metric20212022202320242025TTMMRQ
EPS per share-0.359-1.084-1.35-2.497-2.192-2.49-
Sales USD millions000000-
Shares million shares2626272732-40
Quarterly
MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
EPS per share-0.622-0.563-0.561-0.654-0.523-0.507-0.798-0.646-0.54
Sales USD millions000000000
Shares million shares272727272732353540

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/2021
Total Revenue0.000.000.000.000.00-100.0%0.21
Cost of Goods Sold Incl. D&A0.640.66+32.0%0.50+35.1%0.37+8.8%0.34+142.9%0.14
Gross Profit-0.64-0.66-0.50-0.37-0.34-585.7%0.07
Selling, General and Administrative Excl. Other99.5165.70-3.5%68.11+81.9%37.44+29.8%28.85+138.0%12.12
Research and Development72.5645.62-2.9%47.00+55.2%30.29+27.9%23.69+183.0%8.37
Other Operating Expense0.000.000.000.000.000.00
Operating Income-100.15-66.36-68.61-37.81-29.19-12.06
Interest Expense2.072.47+79.0%1.38+0.7%1.37-0.00
Unusual Expense0.791.01+236.7%0.30-0.53-243.2%0.37+236.4%0.11
Net Income Before Taxes-95.18-63.24-61.43-36.30-27.71-9.19
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-95.18-63.24-61.43-36.30-27.71-9.19
Net Income From Continuing Operations-95.18-63.24-61.43-36.30-27.71-9.19
Net Income-95.18-63.24-61.43-36.30-27.71-9.19
EPS (Recurring) per share-2.03-2.17-2.49-1.36-1.07-0.36
EPS (Basic, Before Extraordinaries) per share-2.49-2.19-2.50-1.35-1.08-0.36
EPS (Diluted) per share-2.49-2.19-2.50-1.35-1.08-0.36
EBITDA-99.51-65.70-68.11-37.44-28.85-11.91
Non-Operating Income (Expense)7.836.60-25.4%8.85+276.6%2.35+27.0%1.85-37.9%2.98
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense11.848.11+6.3%7.63+164.0%2.89+64.2%1.76+665.2%0.23
Gross Margin %-----30.95
Operating Margin %------5,740.95
Net Margin %------4,374.76
Shares Outstanding million shares39.9831.92+18.3%26.99+0.4%26.88+5.1%25.570.0%25.57
Market Capitalization1,228.191,228.19+976.6%114.08+0.7%113.27--

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.10-37.5%0.20+100.0%0.18+5.9%0.16-5.9%0.16-20.0%0.100.0%0.17+70.0%0.17+88.9%
Gross Profit-0.10-0.20-0.18-0.16-0.16-0.10-0.17-0.17
Selling, General and Administrative Excl. Other26.73+80.7%28.93+55.7%26.95+73.8%16.90+0.4%14.79-20.9%18.58+1.9%15.51+8.5%16.83+44.2%
Research and Development18.16+72.5%22.11+68.5%20.29+103.5%12.00+11.1%10.53-19.4%13.12-0.5%9.97+0.2%10.80+12.0%
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-26.82-29.13-27.14-17.05-14.95-18.68-15.68-17.00
Interest Expense0.46-29.2%0.49-24.6%0.55-8.3%0.57+72.7%0.65+85.7%0.65+85.7%0.60+71.4%0.33-8.3%
Unusual Expense0.43+290.9%0.13+116.7%0.12-83.3%0.11+1000.0%0.11+120.0%0.060.72+200.0%0.01
Net Income Before Taxes-25.12-27.64-26.24-16.18-14.18-17.71-15.17-15.20
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-25.12-27.64-26.24-16.18-14.18-17.71-15.17-15.20
Net Income From Continuing Operations-25.12-27.64-26.24-16.18-14.18-17.71-15.17-15.20
Net Income-25.12-27.64-26.24-16.18-14.18-17.71-15.17-15.20
EPS (Recurring) per share-0.53-0.64-0.80-0.50-0.52-0.65-0.54-0.56
EPS (Basic, Before Extraordinaries) per share-0.54-0.65-0.80-0.51-0.52-0.65-0.56-0.56
EPS (Diluted) per share-0.54-0.65-0.80-0.51-0.52-0.65-0.56-0.56
EBITDA-26.73-28.93-26.95-16.90-14.79-18.58-15.51-16.83
Non-Operating Income (Expense)2.60+69.9%2.11+25.6%1.56-14.8%1.56-26.8%1.53-38.8%1.68-36.8%1.83+17.3%2.13+187.8%
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.52+60.7%3.55+77.5%2.82+43.1%1.95+24.2%2.19+9.5%2.00+5.8%1.97-9.6%1.57+157.4%
Shares Outstanding million shares39.98+47.1%35.09+29.6%35.05+29.5%31.92+18.3%27.17+0.7%27.07+0.4%27.07+0.7%26.99+0.4%
Market Capitalization1,228.19+1028.3%926.13+1455.0%718.13+1128.0%552.98+384.7%108.85-64.7%59.56-79.3%58.48-85.8%114.08-72.4%

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/2021
Cash & Short Term Investments176.48+4.9%168.23+103.8%82.55+70.8%48.34+88.1%25.70
Short Term Receivables0.000.00-100.0%0.01-98.2%0.55-68.4%1.74
Inventories0.000.000.000.000.00
Other Current Assets1.23+10.8%1.11-60.8%2.83+757.6%0.33+37.5%0.24
Total Current Assets177.72+4.9%169.34+98.3%85.39+73.5%49.22+77.8%27.68
Net Property, Plant & Equipment6.13-20.4%7.70+593.7%1.11-29.7%1.58+49.1%1.06
Total Investments and Advances0.500.0%0.500.000.000.00
Other Assets0.340.00-100.0%0.13+116.7%0.06+20.0%0.05
Total Assets184.69+4.0%177.54+104.9%86.63+70.4%50.85+76.6%28.79
Short Term Debt Incl. Current Port. of LT Debt1.74+100.0%0.87+625.0%0.12-57.1%0.280.00
Accounts Payable1.88+19.0%1.58+47.7%1.07-33.5%1.61+168.3%0.60
Other Current Liabilities7.71+2.0%7.56+71.4%4.41+20.2%3.67+203.3%1.21
Total Current Liabilities11.32+13.1%10.01+78.4%5.61+0.9%5.56+207.2%1.81
Long Term Debt22.22+38.3%16.07-89.4%151.34+85.0%81.82+114.4%38.16
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.000.00-100.0%1.35-28.2%1.88+44.6%1.30
Total Liabilities33.55+28.6%26.08-83.5%158.30+77.3%89.26+116.3%41.27
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity151.14-0.2%151.46-71.67-38.41-12.48
Total Shareholders Equity151.14-0.2%151.46-71.67-38.41-12.48
Accumulated Minority Interest0.000.000.000.000.00
Total Equity151.14-0.2%151.46-71.67-38.41-12.48
Total Liabilities & Stockholders Equity184.69+4.0%177.54+104.9%86.63+70.4%50.85+76.6%28.79
Book Value Per Share per share4.73-15.7%5.61-2.67-1.50-0.49
Tangible Book Value Per Share per share4.73-15.7%5.61-2.67-1.50-0.49
Full-Time Employees people68-10.5%76+20.6%63--
Price to Book Ratio ratio4.130.690.69--
Return on Assets %-34.92-46.51-52.81-69.58-
Return on Equity %-41.80-153.99---
Return on Invested Capital %-36.48-36.67-45.57-63.82-35.77
Quick Ratio ratio15.6916.9215.228.8515.30
Current Ratio ratio15.6916.9215.228.8515.30

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/2021
Net Income-95.18-63.24-61.43-36.30-27.71-9.19
Depreciation0.710.66+32.0%0.50+35.1%0.37+8.8%0.34+142.9%0.14
Other Funds (Non Cash)14.1910.78+14.1%9.45+197.2%3.18+32.5%2.40+585.7%0.35
Funds from Operations-80.28-51.80-51.48-32.75-24.97-8.69
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.160.03-99.3%4.06-0.70-115.3%4.58-0.57
Cash from Operating Activities-79.12-51.77-47.42-33.45-20.39-9.26
Capital Expenditures-0.56-0.02-2.08-0.47-0.73-0.68
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.56-0.02-2.08-0.47-0.73-0.68
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock261.4149.98-62.8%134.44+93.4%69.52+103.8%34.12+7.7%31.69
Repurchase of Common Pref Stock-0.17-0.170.000.000.000.00
Sale of Common Pref Stock261.5750.15-62.7%134.44+93.4%69.52+103.8%34.12+7.7%31.69
Proceedsfrom Stock Options89.38-0.56-100.4%134.25+93.1%69.52+103.8%34.12+7.7%31.69
Issuance or Reduction of Debt, Net0.0010.10+708.0%1.250.00-100.0%9.670.00
Change in Long Term Debt0.0010.10+708.0%1.250.00-100.0%9.670.00
Issuance of Long Term Debt0.0020.44+1535.2%1.250.00-100.0%9.670.00
Reduction of Long Term Debt0.00-10.340.000.000.000.00
Net Financing Active Other Cash Flow-0.190.000.00-1.390.000.00
Other Financing Activities Uses-0.190.000.00-1.390.000.00
Cash from Financing Activities261.2260.08-55.7%135.69+99.2%68.13+55.6%43.79+38.2%31.69
Exchange Rate Effect-0.01-0.03-0.01-0.01-0.02-0.05
Net Change in Cash181.538.26-90.4%86.18+152.0%34.20+51.1%22.64+4.3%21.70
Free Cash Flow-79.68-51.79-49.50-33.92-21.13-9.94
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Cash & Short Term Investments319.34+131.7%243.73+65.1%263.76+64.1%176.48+4.9%137.82-24.1%147.59-23.6%160.75-21.9%168.23+103.8%
Short Term Receivables0.000.000.000.000.000.000.000.00-100.0%
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets3.85+136.2%3.59+58.8%5.36+93.5%1.23+10.8%1.63-10.4%2.26-1.3%2.77+14.5%1.11-60.8%
Total Current Assets323.20+131.8%247.32+65.0%269.13+64.6%177.72+4.9%139.45-24.0%149.85-23.3%163.52-21.5%169.34+98.3%
Net Property, Plant & Equipment2.74-57.8%5.91-15.1%6.29-14.1%6.13-20.4%6.49-14.4%6.96+383.3%7.32+372.3%7.70+593.7%
Total Investments and Advances0.500.0%0.500.0%0.500.0%0.500.0%0.500.0%0.500.0%0.500.50
Other Assets0.07-87.7%0.34-40.4%0.34-40.4%0.340.570.570.57+850.0%0.00-100.0%
Total Assets326.50+122.1%254.07+60.9%276.26+60.7%184.69+4.0%147.01-23.3%157.88-20.0%171.91-18.1%177.54+104.9%
Short Term Debt Incl. Current Port. of LT Debt5.88+425.0%5.13+428.9%3.44+290.9%1.74+100.0%1.12-73.6%0.97-58.2%0.88-26.7%0.87+625.0%
Accounts Payable3.47+68.4%4.02+140.7%3.37+144.2%1.88+19.0%2.06-8.4%1.67-9.2%1.38-42.7%1.58+47.7%
Other Current Liabilities8.48+44.5%7.50+36.6%6.31+26.2%7.71+2.0%5.87-21.9%5.49-3.3%5.00+13.9%7.56+71.4%
Total Current Liabilities17.84+97.3%16.65+104.8%13.12+80.7%11.32+13.1%9.04-35.5%8.13-17.4%7.26-9.4%10.01+78.4%
Long Term Debt12.14-54.0%18.16-31.1%19.77-22.7%22.22+38.3%26.40+110.5%26.34+240.3%25.56+190.1%16.07-89.4%
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.00-100.0%
Total Liabilities29.98-15.4%34.82+1.0%32.89+0.2%33.55+28.6%35.45+33.5%34.47+96.1%32.82+95.1%26.08-83.5%
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity296.53+165.8%219.25+77.7%243.37+75.0%151.14-0.2%111.56-32.4%123.41-31.4%139.10-28.0%151.46
Total Shareholders Equity296.53+165.8%219.25+77.7%243.37+75.0%151.14-0.2%111.56-32.4%123.41-31.4%139.10-28.0%151.46
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity296.53+165.8%219.25+77.7%243.37+75.0%151.14-0.2%111.56-32.4%123.41-31.4%139.10-28.0%151.46
Total Liabilities & Stockholders Equity326.50+122.1%254.07+60.9%276.26+60.7%184.69+4.0%147.01-23.3%157.88-20.0%171.91-18.1%177.54+104.9%
Book Value Per Share per share7.42+80.5%6.25+37.1%6.94+35.0%4.73-15.7%4.11-32.8%4.56-31.6%5.14-28.4%5.61
Tangible Book Value Per Share per share7.42+80.5%6.25+37.1%6.94+35.0%4.73-15.7%4.11-32.8%4.56-31.6%5.14-28.4%5.61
Full-Time Employees people---68-10.5%---76
Price to Book Ratio ratio4.133.804.754.330.880.430.380.69
Return on Assets %-40.20-40.90-33.16-34.92-36.77-36.52-33.09-46.51
Return on Equity %-46.65-49.17-38.86-41.80-45.01-42.78-38.04-153.99
Return on Invested Capital %-8.14-11.64-9.97-9.33-10.28-11.82-9.21-9.07
Quick Ratio ratio18.1214.8520.5215.6915.4218.4322.5316.92
Current Ratio ratio18.1214.8520.5215.6915.4218.4322.5316.92

Cash flow, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Net Income-25.12-27.64-26.24-16.18-14.18-17.71-15.17-15.20
Depreciation0.18+12.5%0.18+5.9%0.18+5.9%0.16-5.9%0.16+33.3%0.17+54.5%0.17+70.0%0.17+88.9%
Other Funds (Non Cash)4.37+56.1%4.05+64.6%3.35+8.1%2.41+26.2%2.80+30.2%2.46-11.8%3.10+19.7%1.91+151.3%
Funds from Operations-20.57-23.40-22.70-13.62-11.21-15.07-11.90-13.12
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.19-114.6%3.64+182.2%-4.392.10+2000.0%1.30-53.4%1.29-9.8%-4.660.10
Cash from Operating Activities-20.76-19.76-27.09-11.52-9.92-13.78-16.56-13.02
Capital Expenditures0.000.00-0.560.000.000.00-0.02-0.51
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.560.000.000.00-0.02-0.51
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock96.36+64140.0%-0.27115.13+57465.0%50.19+100280.0%0.15+114.3%-0.560.20-99.9%0.05-99.9%
Repurchase of Common Pref Stock0.000.000.00-0.170.000.000.000.00
Sale of Common Pref Stock96.36+64140.0%-0.27115.13+57465.0%50.35+100600.0%0.15+114.3%-0.560.20-99.9%0.05-99.9%
Proceedsfrom Stock Options-25.40-0.35115.120.000.00-0.560.00-100.0%0.00-100.0%
Issuance or Reduction of Debt, Net0.000.00-100.0%0.00-100.0%0.000.00-100.0%0.759.350.00
Change in Long Term Debt0.000.00-100.0%0.00-100.0%0.000.00-100.0%0.759.350.00
Issuance of Long Term Debt0.000.00-100.0%0.00-100.0%0.000.00-100.0%0.7519.690.00
Reduction of Long Term Debt0.000.000.000.000.000.00-10.340.00
Net Financing Active Other Cash Flow0.000.00-100.0%-0.190.000.000.42-0.420.00
Other Financing Activities Uses0.000.00-100.0%-0.190.000.000.42-0.420.00
Cash from Financing Activities96.36+64140.0%-0.27-144.3%114.94+1158.9%50.19+100280.0%0.15-88.6%0.619.13-93.2%0.05-99.9%
Exchange Rate Effect0.000.00-0.02-0.00-100.0%-0.00-0.00-0.020.01
Net Change in Cash75.61-20.0387.2838.67-9.77-13.17-7.47-106.1%-13.47-143.1%
Free Cash Flow-20.76-19.76-27.65-11.52-9.92-13.78-16.58-13.53

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.99%5.7M35.6M559.89K
2026-10-1514.64%5.2M35.6M543.62K
2026-09-3013.09%4.7M35.6M545.30K
2026-09-1511.72%4.2M35.6M556.42K
2026-08-3110.77%3.8M35.6M540.14K
2026-08-1410.00%3.6M35.6M515.29K
2026-07-319.21%3.2M35.1M493.75K
2026-07-158.81%3.1M35.1M464.14K
2026-06-307.60%2.4M31.7M419.04K
2026-06-155.11%1.6M31.7M344.38K
2026-05-295.39%1.7M31.4M324.20K
2026-05-155.13%1.6M31.4M308.48K
2026-04-305.53%1.6M28.7M293.80K
2026-04-157.63%2.2M28.7M278.81K
2026-03-316.99%2.1M29.3M245.64K
2026-03-136.76%2.0M29.3M281.33K
2026-02-277.16%2.0M28.5M284.43K
2026-02-137.49%2.1M28.5M309.38K
2026-01-307.67%2.1M27.9M343.68K
2026-01-157.80%2.2M27.9M707.30K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.5017.3020.500.00840.2%0.000.000.914-0.5000.007
call15.0014.8018.000.00700.7%0.000.000.885-0.5120.009
call17.5012.0015.500.00587.3%0.000.000.855-0.5080.010
call20.009.5013.000.00490.9%0.000.000.822-0.4920.012
call22.507.2010.502.30405.8%1400.000.783-0.4670.013
call25.004.508.001.50328.3%2380.000.737-0.4330.015
call30.001.104.900.00259.7%0.000.000.602-0.3130.017
call35.000.004.700.60353.5%8.001.000.499-0.4040.018
call40.000.004.900.90426.8%12.000.000.453-0.4840.018
call45.000.002.800.30456.4%14.000.000.426-0.5290.018
put12.500.004.900.00559.1%0.000.00-0.067-0.2050.006
put15.000.004.900.40463.2%5.000.00-0.083-0.2000.007
put17.500.004.900.55383.0%4.000.00-0.102-0.1920.008
put20.000.004.901.47311.3%1010.00-0.123-0.1740.010
put22.500.004.900.85251.0%1690.00-0.154-0.1670.011
put25.000.004.901.02339.8%4.000.00-0.225-0.3030.014
put30.000.004.900.00297.0%0.000.00-0.398-0.3100.017
put35.002.005.308.80130.0%1.000.00-0.501-0.4000.018
put40.007.0010.0010.10172.0%2.000.00-0.546-0.4790.018
put45.0012.0015.400.00253.2%0.000.00-0.668-0.3820.016

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-30SCHEDULE 13GSEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-09-29144Filing for proposed sale of securities under Rule 144.SEC
2026-08-278-KCurrent report2026-08-26SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-07-27SCHEDULE 13GSEC
2026-07-20SCHEDULE 13GSEC
2026-07-148-KCurrent report2026-07-13SEC
2026-07-14424B5SEC
2026-07-138-KCurrent report2026-07-13SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-293Initial statement of beneficial ownership of securities2026-05-27SEC
2026-05-288-KCurrent report2026-05-27SEC
2026-05-154Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13GSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09003.57M2
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Alpha Wave Global, LP10.57%
Commodore Capital LP7.76%
BlackRock, Inc.6.04%
PERCEPTIVE ADVISORS LLC4.59%
ADAGE CAPITAL PARTNERS GP, L.L.C.4.56%
VANGUARD CAPITAL MANAGEMENT LLC3.96%
Spruce Street Capital LP3.86%
Vivo Capital, LLC3.44%
FRANKLIN TEMPLETON INC2.53%
ARMISTICE CAPITAL, LLC2.46%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.88%
iShares Russell 2000 ETF1.89%
VANGUARD EXTENDED MARKET INDEX FUND0.99%
Fidelity Small Cap Index Fund0.74%
iShares Russell 2000 Growth ETF0.69%
T. Rowe Price Health Sciences Fund, Inc.0.65%
iShares Biotechnology ETF0.63%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF0.54%
Franklin Biotechnology Discovery Fund0.47%
VANGUARD RUSSELL 2000 INDEX FUND0.38%

OakChart. ANRO. Cached 15 minutes. Terms